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Due to the complexity of the case, the format of patient information, followed by discussion at the  
appropriate point of the case study, has been adopted.
Nutritional management of a complicated surgical  
patient by means of fistuloclysis
Introduction
A fistula is defined as an abnormal communication between two 
organs, an organ and the skin, or an organ and a wound.1 Up to 
70% of patients with fistulae present with malnutrition.1 Enteral 
nutrition (EN) has considerable advantages over parenteral nutrition 
(PN) support, including improved gut barrier function, a reduction 
in infectious morbidity and improved immune function.2 EN support 
remains the preferred route of nutrition support in patients with 
fistulae, unless it causes a significant increase in fistula output, 
abdominal pain or exacerbates diarrhoea.1 Fistuloclysis, i.e. enteral 
feeding via an intestinal fistula, is an effective means of providing 
nutritional support to these patients and can replace the need for 
PN support.3 
Case study (days 0-65)
A 30-year-old male, with no significant past medical history, was 
admitted to hospital with multiple gunshot wounds to the abdomen. 
On admission to hospital, he underwent a damage control 
laparotomy, where he was found to have complete transection at the 
duodenojejunal (DJ) flexure, a transverse colon perforation, a splenic 
laceration, a left kidney injury, multiple small bowel perforations and 
arterial bleeding. The DJ flexure and colonic injuries were repaired 
primarily, a left nephrectomy was performed, the arterial bleed ligated 
and packed, and the small bowel tied off. The patient was transferred 
to the intensive care unit (ICU) on ventilation and inotropic support, 
with an open abdomen. The patient’s anthropometry on admission to 
the ICU was an estimated height and weight of 1.75 m and 75 kg, 
respectively, with a normal body mass index (BMI) of 24.5 kg/m2. 
PN support was started on day 1 of ICU admission, according to The 
European Society for Clinical Nutrition and Metabolism guidelines 
on PN with respect to intensive care.4 The PN prescription provided 
20 kCal/kg non-protein energy (NPE) with 1.7g/kg protein, which 
included 0.4 g/kg of intravenous (IV) glutamine.
Nine relook laparotomies were performed while the patient was in 
the ICU. A feeding jejenostomy was placed at the second relook in an 
attempt to obtain a secure enteral feeding route distal to the duodenal 
injury. The primary repair to the duodenum broke down and required 
re-repair, making successful gastric feeding at that point potentially 
impossible. The feeding jejenostomy was complicated by necrosis, 
and was eventually removed at the last re-look laparotomy. The 
patient had developed a frozen abdomen with fistulae, presumably 
from the initial duodenal injury and site of the feeding jejenostomy. 
After 38 days in ICU, the patient was weighed on a bed scale. 
A weight of 64 kg was recorded, equating to a BMI of 21 kg/m2, 
still within the normal range. He was discharged to the intestinal 
failure unit on day 65 post injury on PN, with an open abdomen with 
vacuum dressing, multiple enteroatmospheric fistulae (EAF) and a 
sacral bedsore. 
Discussion with respect to the case study (days 0-65)
A fistula arising from the gut to any other part of the body is referred 
to as a gastrointestinal fistula, while that between the gut and the 
skin is an enterocutaneous fistula (ECF).1 An EAF is a subset of an 
ECF that arises in the setting of an open abdomen with exposed 
viscera.5,6 An ECF can develop due to complications of injury, intra-
abdominal surgery (75-85% of cases),1 malignancy, inflammatory 
bowel disease, post-radiation therapy for malignancy or due to distal 
obstruction.5 Crohn’s disease is a major contributor to spontaneous 
fistula development, and 40% of patients with this condition will 
develop a fistula in the course of their illness.1 Patients with an open 
abdomen present a high risk for the development of fistulae, with an 
incidence of 5-19%.6
Over the past 30 years, with improvements in wound and skin care, 
the management of sepsis, and the provision of safe and effective 
nutritional support and appropriate timing of surgical intervention, 
the associated mortality of ECFs has been reduced from 65% to 
10%.7 Mortality rates associated with EAF still remain around 10%.7 
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An EAF requires surgery in order to close, while an ECF type of fistula 
with an intact abdominal wall has a spontaneous closure rate of 
50-80%.7 
Fistulae are classified according to output.6 Less than 200 ml effluent 
per day is considered to be low output, while 200-500 ml per day 
is classified as moderate output.6 An ECF effluent of more than 
500 ml per day is considered a high-output fistula and is associated 
with high morbidity and mortality.1,6 Therefore, the treatment 
and management of patients with fistulae focuses on addressing 
sepsis, improving nutritional status, excluding distal obstruction and 
reducing fistulae output.7 
Reducing fistulae output can be achieved by slowing the 
gastrointestinal transit with loperamide and codeine, optimising 
luminal absorption with isotonic feeding and reducing enteric 
secretions.7 Somatostatin is a naturally occurring peptide hormone, 
with an inhibitory effect on gastrointestinal secretions.7 However, it 
has a half-life of only 1-2 minutes, and therefore requires constant 
infusion in order to be effective.8 Synthetic somatostatin analogues 
have been developed with a longer half-life, making intermittent 
administration possible.8 Octreotide is one such analogue.8 Although 
similar to somatostatin, the receptor-binding properties are not the 
same, and their action might not be equivalent.8 It was found in a 
meta-analysis and systematic review published in 2012 that both 
somatostatin and octreotide increased the likelihood of spontaneous 
fistula closure, and were effective in reducing time to closure.8 
However, closure of the fistulae tract largely depends on the anatomy 
of the fistulae tract, and not only the output.8 The review data did 
not show a mortality benefit.8 Somatostatin appeared to be superior 
to octreotide in improving outcome.8 Side-effects associated with 
the use of somatostatin and somatostatin analogues include nausea, 
abdominal cramps, loose stools, mild steatorrhoea and flatulence.8 
These side-effects start within hours of the first dose and appear 
to be dose dependent, but usually subside spontaneously within 
the first few weeks of treatment.8 There is an increased risk of 
gallstones developing in patients treated with somatostatins.8 
Octreotide is often recommended in the literature for use in the 
management of ECF patients, but the literature is not consistent and 
larger randomised control trails are needed. 
Intestinal failure can be defined as a condition resulting from 
obstruction, dysmotility, surgical resection, congenital defect or 
disease-related loss of absorptive ability, and is characterised by the 
inability to maintain protein energy, fluid, electrolytes or micronutrient 
balance.9,10 Patients usually require supplementary PN and/or IV fluid 
to maintain nutrition and fluid status (Table I).11
Case study (days 66-112)
This patient would have been classified as a type 2 intestinal failure 
while in the ICU because of his multiple fistulae and the long duration 
of his intestinal failure.
Table I: Subtypes of intestinal failure9,11
Type Description Management
Type 1 Self-limiting, short term and often perioperative Settles within 7-14 days with conservative management, nasogastric 
drainage and parenteral nutrition support
Common causes include non-mechanical ileus (post surgery, intra-
abdominal sepsis, spinal cord injury, head injury, extra-abdominal 
sepsis and multi-organ failure), and mechanical intestinal obstruction
Type 2 High incidence of mortality Early diagnosis and treatment of abdominal sepsis and adequate 
nutrition support, usually in the form of parenteral nutrition
Usually not self-limiting
Often secondary to abdominal sepsis and intestinal fistulation
Type 3 50% of patients with type 2 intestinal failure develop type 3 intestinal 
failure
Long-term parenteral nutrition support
Table II: Nutrition requirements
Descriptor Energy Protein Micronutrients
Open abdomen12 25-35 kCal/kg NPE 1.5-2.5 g/kg plus 29 g/l effluent
Low-output gastrointestinal 
fistula1
25 kCal/kg TE 1-1.5 g/kg
High-output gastrointestinal 
fistula1
At least 30 kCal/kg TE 1.5-2 g/kg plus 2 g/l effluent 2 x DRIs for vitamins and trace elements. Up to 5 x DRIs 
for vitamin C and zinc. At high risk of vitamin B12, zinc, 
magnesium and selenium deficiency
Short bowel syndrome13,14 PN: 32 kCal/kg TE13 PN: 1-1.5 g/kg13 Typically requires doses higher than the DRI for healthy 
individuals. 
Depends on the remaining gastrointestinal anatomy, e.g. 
ileum resection with vitamin B12 malabsorption
EN: Up to 60 kCal/kg TE14 EN: 1.5-2 g/kg14
DRI: dietary reference intake, EN: enteral nutrition, NPE: non-protein energy, PN: parenteral nutrition, TE: total energy
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His PN regimen was calculated to compensate for his fistula 
losses and open abdomen, using his last actual weight of 64 kg. 
Energy requirements were calculated with the aim of providing 25-
35 kCal/kg NPE and 1.5-2.5 g/kg protein. Protein losses from the 
open abdomen were also taken into consideration.12 Protein losses 
from an open abdomen are estimated to be approximately 29 g/l, 
while fistula losses contain approximately 2 g of protein per litre 
(Table II).12 An average output of 730 ml/day was recorded from 
the open abdomen, inclusive of fistula losses. Protein losses from 
the open abdomen calculated at 29 g/l equated to 21 g of protein. 
Therefore, the PN regimen had to provide 96-160 g of protein (1.5-
2.5 g/kg), plus an additional 21 g/kg to compensate for the losses, 
i.e.117-181 g protein/day. The patient received 140 g protein per 
day, which included 20 g of glutamine (Table III). The patient was 
kept nil per os and only received PN support. 
The patient remained on this PN regimen until he developed a central 
line-associated blood stream infection (CLABSI) requiring removal of 
the central line on day 68. It is practice to remove the central line in 
our intestinal failure unit while the CLABSI is being treated, and to 
reinsert a central line for recommencement of PN once the patient 
has been apyrexial for 48 hours. During this period, patients only 
receive IV fluids via a peripheral line to maintain hydration status 
Table III: Nutrition delivery












Volume (ml) 2 400 2 400 1 000 2 600 2 620 2 000 -
Total energy (kCal/kg) 36 41 22 50 44 38 84
Non-protein energy 
(kCal/kg)
27 31 16 40 33 31 68
Protein (g/kg) 2.2 2.6 1.4 2.6 2.7 1.7 4
Glutamine (g/kg) 0.3 0.4 0.58 0.45 0.5 - -





2.75 g/kg 6 g/kg 4 mg/kg/minute 5.5 g/kg -
Na (mmol) 116.5 116.5 35 77.7 115.5 70 -
K (mmol) 52.5 52.5 51 91 60 102 -
Cl (mmol) 130.5 130.5 83 145.7 165.5 166 -
PO4 21.2 21.2 48 65.7 21.5 42.5 -
Water-soluble 
vitamins
























Cl: chloride, EN: enteral nutrition, K: potassium, Na: sodium, PN: parenteral nutrition, PO4: phosphate, RDA: recommended dietary allowance, TE: total energy





Day  73 Day 80 Day 90 Day 112 Day 133 Day 154 Day 171 Day 182 Day 189 Day 245 Day 318
Urea (mmol/l) 2.6-7 3.3 2.1 6.5 5.1 2 6.2 8.4 7.9 6.9 3.6 4.6
Creatinine (µmol/l) 64-104 88 70 53 51 68 68 80 115 93 98 101
Total bilirubin 
(µmol/l)
0-21 7 12 9 3 3 3 8 5 4 9 9
Conjugated bilirubin 
(µmol/l)
0-6 3 6 3 2 < 1 < 1 - 2 2 3 2
Alkaline 
phosphatase (U/L)
40-120 96 149 173 91 83 250 444 175 141 99 83
γ-glutamyl 
transferase (U/L)
0-60 35 - 73 28 15 86 183 46 47 50 15
Alanine 
transaminase (U/L) 
5-40 18 31 31 8 12 27 112 15 18 21 12
Aspartate 
transaminase (U/L)
5-40 8 26 28 8 16 29 113 14 13 13 15
Albumin (g/l) 35-52 17 20 21 17 14 14 29 27 29 37 39
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and oral intake, as tolerated. The patient’s weight had 
deteriorated to 55 kg on day 68 of treatment. 
On day 74 of treatment, six days later, his PN was restarted 
on the same regimen as before, and he was allowed 
to continue the full ward diet (providing approximately 
1 800 kCal TE and 80 g protein), as tolerated. Patients with 
ECF should be allowed to eat orally if they wish to do so 
because of the psychological benefit that is derived from 
it.6 Oral intake should be abandoned if the fistula output 
increases to unmanageable levels in terms of volume and 
electrolyte abnormalities.6 His appetite was poor and he had 
ongoing episodes of vomiting.
The biochemistry, repeated on days 80 and 90, showed 
ongoing deranged liver function tests and hypoalbuminaemia 
(Table IV). The deranged liver enzymes were thought to be 
owing to prolonged PN support, as well as ongoing sepsis.15 
His PN regimen included a fish oil-containing lipid emulsion. 
Lipids were restricted to < 1 g/kg and he was started on 
cyclic PN over 18 hours. His oral intake was encouraged in 
an attempt to optimise the enteral route, in order to improve 
his deteriorating liver function tests (Table IV).15
The patient underwent a fistulogram on day 93 in order 
to delineate the anatomy of the gastrointestinal tract. The 
fistulogram showed approximately 60 cm of small bowel 
distal to the most distal fistula with colon in situ and no 
distal defects or obstructions. At this stage, he had an 
average fistula output of 800 ml/day and vomited 400 ml/
day on average. He had a gastroscopy to rule out a gastric 
outlet obstruction as the cause of the ongoing vomiting, but 
a mechanical or functional cause was not found. On day 95 
post injury, the distal fistula was canulated and the patient 
was started on fistuloclysis. PN support continued on the 
same regimen, with negligible oral intake (< 150 kCal taken 
by mouth).
The fistula effluent re-infusion was started at 21 ml/hour 
via the fistuloclysis catheter, and increased daily until all 
of the effluent was being re-infused. By re-infusing the 
fistula output, the losses via a fistula are eliminated and 
there is no need to compensate for them. The length of the 
bowel available for absorption and enteral intake need to 
be taken into consideration when calculating energy requirements 
and the need for ongoing PN support.  Seventeen days after starting 
fistuloclysis, day 112 post injury, the liver enzymes normalised. 
Despite ongoing PN support, his albumin remained low at 17 g/l 
(Table IV). 
Discussion with respect to the case study (days 
66-112)
The process of a fistulogram refers to the injection of contrast into 
the most distal fistula through a thin catheter. X-rays of the abdomen 
are then taken to assess the flow of contrast and exclude any distal 
obstruction or fistulae, and to determine the location of the fistula 
and the length of the distal bowel (Figure 1). If a patient is deemed 
to be a suitable candidate for fistuloclysis, a catheter is inserted into 
the fistula (Figures 2 and 3).
The skin is sprayed to protect it against the stoma or fistula effluent. 
A Foley’s catheter is inserted into the stoma or fistula, and advanced 
down the distal limb for fistuloclysis
The stoma or fistula is covered with a suitable stoma bag and the 
Foley’s catheter inserted and secured through a hole in the bag. 
A feed administration set is connected to the catheter. The double 
lumen catheter makes simultaneous administration of the enteral 
feed and enteric content possible.
Contrast in the small 
bowel lumen
The introduction of contrast 
into the distal small bowel limb
Small bowel fistula with 
contrast extravasation
Figure 1: Fistulogram demonstrating the free flow of contrast distal to the fistula or stoma 
to exclude distal obstruction or fistulae prior to commencing fistuloclysis
The skin is prepared to apply 
the stoma bag with protective 
spray
Foley’s catheter inserted 
into the fistula or stoma for 
fistuloclysis
Figure 2: The insertion of a Foley’s catheter and preparation of the skin 
Foley’s catheter inserted and 
secured through a hole in the 
stoma bag
Feed administration set 
attached to the Foley’s catheter 
for feed administration. The 
double lumen makes the 
simultaneous administration 
of enteral feed and enteric 
content possible
Stoma or fistula covered with 
the stoma bag
Figure 3: The insertion of a Foley’s catheter and the accompanying preparations
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Fistuloclysis refers to enteral feeding via an intestinal fistula, and 
is an effective means of providing nutritional support.16 Suitable 
patients for this approach include those with a distal fistula opening 
that can be intubated with a balloon-retained gastrostomy tube, no 
evidence of distal intestinal obstruction and at least 75 cm of small 
bowel distal to the fistula.5
Fistuloclysis successfully replaced PN in 11 of 12 patients in a 
series described by Teubner et al, and increased body weight and 
serum albumin, as well as decreasing hospital length of stay.3 
Complications were not associated with fistuloclysis, and the 
method was considerably more cost-effective.3 The nutritional 
status was maintained for a median of 155 days (a range of 19-
422) until definitive reconstructive surgery could be undertaken in 
nine of the 11 patients.3 Two patients who did not undergo surgery 
were maintained on fistuloclysis for nine months.3 One patient died 
at home due to ischaemic heart disease, while the second could not 
undergo reconstructive surgery because of medical co-morbidities.3
Wu et al found that fistuloclysis could successfully improve liver 
function and overall nutritional status in patients with high-output 
enteric fistulae.2 Ninety-five patients met the entry criteria in this 
study2 and were enrolled. They were divided into a control group 
who received EN only, and a fistuloclysis group who received EN 
and fistuloclysis. Patients in the fistuloclysis group were further 
divided into three subgroups with regard to the location of the fistula: 
group 1, patients with jejuna-ileal fistulae; group 2, patients with 
biliary fistulae and group 3, patients with duodenal fistulae. EN was 
administered into the distal fistula or nasojejunally in the case of 
biliary fistulae. The feeding goal was at least 30 kCal/kg/day and 
1.5-2 g/kg protein/day, with an additional 2 g of nitrogen for every 
litre of fistula output. Both groups showed a statistically significant 
decline in hepatic indexes from baseline to 28 days. Similarly, there 
was an increasing trend with regard to the nutritional parameters in 
both groups. The fistuloclysis group showed a statistically significant 
increase in albumin levels. The fistuloclysis group also demonstrated 
a significant reduction in fistula output. With respect to differences 
between the groups receiving fistuloclysis, the biggest improvement 
in total and direct and indirect bilirubin and alkaline phosphatase 
was seen in group 2, i.e. in patients with biliary fistulae. The greatest 
improvement in alanine transaminase and total protein was also 
seen in patients in group 2. Patients in group 1, i.e. patients with 
jejunal-ileal fistulae, showed the least improvement with respect 
to these parameters. In terms of one-year survival, one patient 
(2.9%) in the fistuloclysis group died, while 10 patients (16.7%) in 
the control group died at one year follow-up. In terms of survival 
time, the fistuloclysis plus EN group was significantly (p-value 0.045) 
superior when compared to the group of patients who received 
EN only. 
Fistuloclysis, as a method of nutrition support, has several 
advantages.2 Benefits seen might be because of the improvement 
in liver function and nutritional status, together with a reduction in 
fistula output.2 Up to 70% of patients with fistulae have malnutrition.1 
EN support is the preferred route of nutrition support, unless it 
increases fistula output dramatically, causes increased abdominal 
pain or exacerbates diarrhoea.1 Fistuloclysis could eliminate some of 
the limitations associated with enteral feeding. 
Fistuloclysis also has a better positive impact on liver function tests 
than EN alone.2 This may, in part, be attributable to cholecystokinin 
(CCK) which is produced by the endocrine cells in the duodenum 
and upper jejunum.2 CCK stimulates gallbladder contractility and bile 
secretion.2 CCK is secreted in response to fat, protein and amino 
acid in the duodenum.2 Trypsin-sensitive monitor peptide in the 
upper intestinal lumen is another potent CCK-releasing factor, but 
it might be lost through fistula output.2 Therefore, supporting the 
digestive system through fistuloclysis might improve CCK secretion, 
and thereby enhance cholestasis.2
Additionally, fistuloclysis provides salivary amylase, gastric pepsin 
and pancreatic enzymes, as well as bile acid which is necessary 
for optimal EN utilisation.2 The fistula effluent also has the perfect 
pH to activate proenzymes and appropriate enzyme components 
for optimal EN absorption.2 Bile acid in the intact gut is secreted in 
the duodenum, absorbed in the terminal ileum and recycled to the 
liver.2 This cycle is interrupted in the patient with a fistula, leading 
to a lack of bile acid and the subsequent malabsorption of fatty 
acid, phospholipids and fat-soluble vitamins.2 The enterohepatic 
circulation of bile acid can be restored with fistuloclysis, and 
improvements in nutritional status achieved.2
High output from enteric fistulae is associated with high fluid and 
electrolyte losses, resulting in hyponatraemia, hypochloraemia, 
hypokalaemia, metabolic acidosis or alkalosis and renal dysfunction.2 
Fistuloclysis has the ability to decrease fistula output, probably 
through an inhibitory effect on upper gastrointestinal secretions.2 
It is speculated that this might be attributable to the restoration of 
bowel continuity and physiological digestive processes.2
Case study (days 113-157)
The patient developed another episode of CLABSI, and the central 
line was removed again on day 113 of treatment. His oral intake 
remained poor, and in an attempt to meet the requirements enterally, 
and to avoid the need for ongoing PN, he was started on a semi-
elemental enteral feed via the fistuloclysis catheter. He also started 
on enteral glutamine at 0.6 g/kg oral administration. The prescribed 
amount of feed was 2 300 kCal TE (45 kCal/kg actual bodyweight) 
and 112 g (2.2 g/kg actual bodyweight) protein. On average, the 
patient only received 1 000 kCal total energy and 44 g of protein, 
less than 50% of the prescribed daily calories and protein. The 
semi-elemental feed was high in medium-chain triglycerides to 
optimise the energy absorptive capacity of the colon in view of the 
very short distal small bowel remnant available for feeding.14 The 
patient’s oral intake from the ward diet and supplements remained 
negligible (< 150 kCal taken by mouth). He continued to receive the 
recommended dietary allowance for fat-soluble and water-soluble 
vitamins and trace elements intravenously. 
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The patient passed 3-5 loose stools per day, and tested negative 
for Clostridium difficile on day 118. He maintained his weight at 52 
kg, but his albumin deteriorated to 14 g/l. His liver function tests 
normalised off PN support (Table IV). After 20 days of fistuloclysis and 
semi-elemental feeds via the distal limb, day 133 in total, the patient 
was restarted on supplemental PN, while continuing fistuloclysis and 
additional semi-elemental enteral feeds, as previously defined.
He had a repeat computed tomography scan on day 140, and was 
found to have only 10 cm of small bowel distal to the most distal 
fistula. Fistuloclysis and the additional feeds were stopped, and 
the patient was restarted on full PN support (Table III). During this 
period of fistuloclysis (53 days), he had an average fistula output of 
1 000 ml per day, of which 75% was re-infused via fistuloclysis. The 
PN regimen contained a 100% soybean lipid emulsion and his liver 
enzymes deteriorated significantly (Table IV). His albumin remained 
low and his weight remained stable at 52 kg. 
On day 157 post injury, he went to theatre for surgery. Intraoperatively, 
there were very dense adhesions, with a fistula 80 cm distal to the DJ 
flexure and a chronic abscess cavity. There was 40 cm of small bowel 
with multiple iatrogenic enterotomies secondary to mobilisation of 
the segment distal to the proximal fistula. A decision was made to 
resect the 40 cm segment. An iatrogenic serosal injury to the second 
part of the duodenum was primarily repaired. The two ends were 
brought out as a double-barrel stoma, and enterotomies distal to 
the stoma were also repaired primarily. Post surgery, the patient’s 
gastrointestinal anatomy was 80 cm of small bowel proximally and 
40 cm of small bowel distally to a double-barrel stoma, with the 
ileocaecal valve and the colon in situ. Skin closure was achieved, 
but the abdominal wall was left open. A new tunnelled central line 
was placed. Owing to the short remnant of small intestine, 120 cm 
in total, the patient was classified as a short bowel syndrome (SBS) 
patient.
Discussion with respect to the case study  
(days 113-157)
SBS refers to a condition in which patients present with 
malabsorption-related diarrhoea, dehydration, electrolyte 
disturbances and malnutrition secondary to poor digestive and 
absorptive capacity, as a result of a reduced functional intestinal 
area.11,17 SBS is often a result of surgical resection, but can also 
be caused by other conditions that influence absorptive capacity 
in the absence of surgical resection, including radiation enteritis, 
chronic intestinal pseudo-obstruction and congenital villus atrophy.17 
Intestinal failure due to SBS is mostly due to massive intestinal loss 
as a result of surgery, trauma or infarction. Less commonly, it is 
associated with congenital defect or loss of absorptive surface as 
a result of disease.9 
Normal lengths of small bowel differ significantly, from 300-850 
cm.9 Evidence suggests that patients with less than 200 cm of 
small bowel are likely to develop intestinal failure, a number that 
is of little significance in practice.9 Although the length of remaining 
bowel correlates with a patient’s degree of nutritional autonomy, 
the location of the resection and condition of the remaining bowel 
also play a role.9,14 SBS accounts for nearly 80% of long-term 
PN patients18,19 since all SBS patients require PN support in the 
immediate postoperative phase to maintain nutritional status.20 
Some patients can be weaned off PN, while others might require 
long-term PN support.20
Case study (days 158-190)
The patient continued PN postoperatively and had very poor oral 
intake. On day 14 post surgery, day 171 of treatment in total, he 
developed another episode of CLABSI and the central line was 
removed and PN stopped. On biochemistry review, his liver enzymes 
remained increased, but albumin had improved to 29 g/l (Table IV). 
A nasogastric tube was placed and the patient was started on a 
semi-elemental enteral feed, the distal stoma was canulated and 
the patient restarted fistuloclysis. He was weaned onto a standard 
polymeric feed within five days and oral intake was encouraged 
(Table III). Twenty-five days post surgery, day 182 in total, his weight 
improved to 53 kg and his albumin was 27 g/l. The liver function 
tests improved (Table IV).
He was discharged home 33 days post surgery, day 190 of treatment 
in total, on oral supplements and fistuloclysis. He required two 
readmissions for dehydration in the month following discharge. 
During this time, he maintained his weight and his albumin improved 
to 38 g/l. At his second readmission, he remained in hospital awaiting 
definitive surgery. He coped well with oral intake and twice took the 
full ward diet and additional oral supplements, providing 84 kCal/kg 
TE and 4 g/kg protein, while he continued fistuloclysis.
Discussion with respect to the case study  
(days 158-190)
Patients with a very short remnant bowel and patients absorbing less 
than a third of their intake typically require long-term PN support, 
while others might be able to maintain nutritional status through 
hyperphagia.20 Hyperphagia is defined as a >1.5-fold increase in 
calories over resting energy expenditure.20
Woolf et al found that SBS patients absorbed approximately 62% 
of delivered energy. The absorption of fat, carbohydrate and protein 
was 54%, 61% and 81%, respectively.14 Calorie provision, of up to 
60 kCal/kg bodyweight/day via the enteral route might be necessary 
to maintain body weight with a protein intake of 1.5-2 g/kg.14 If 
the colon is intact, the delivery of large amounts of carbohydrate 
can improve the energy balance through short-chain fatty acid 
production in the colon.13,14 
Case study (days 191-396)
The patient underwent definitive surgery 247 days post his initial 
injury. His weight was stable at 53 kg and his albumin had improved 
to 37 g/l. The liver function tests were all normal. His postoperative 
gastrointestinal anatomy was 120 cm of small bowel, with ileocaecal 
valve and colon in situ. He was discharged on day five postoperatively 
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on an oral intake with oral supplementation. Oral supplementation 
was provided in the form of three servings of a polymeric powdered 
supplement, providing 690 kCal TE and 30 g protein.
He had been on fistuloclysis for 128 days in total, and was managed 
as an outpatient for 28 days during his total hospital stay of 252 
days. He had an average stoma or fistula output of 1 400 ml per 
day, on average of which 60% was re-infused via fistuloclysis. 
During the total period of fistuloclysis, he had seven documented 
incidences of fistuloclysis catheter-related complications, limited to 
tube dislodgement or blockage of the catheter in this patient. Other 
possible catheter-related complications included skin corrosion from 
effluent leaking onto the skin, as well as a very rare complication of 
a “swallowed” feeding tube, in which the feeding tube was ingested 
into the intestine by peristalsis.2 It is unknown if feeding tubes delay 
the spontaneous healing of fistulae.2 
At follow-up five months post discharge (day 396 post injury), 
the patient’s weight improved to 67 kg. By then, he had regained 
nutritional autonomy. At the time of writing this, he was awaiting 
surgical repair of a large ventral hernia secondary to his open 
abdomen. 
Conclusion
The nutritional management of patients with grade 2 and grade 3 
intestinal failure remains a challenge. Nutritional intervention and 
successful nutritional rehabilitation are often limited by the ability to 
provide long-term PN support. Owing to line sepsis, limited vascular 
access, PN-associated liver disease and cost, PN is not always a 
sustainable solution. Fistuloclysis has been demonstrated to be safe 
and effective in this group of patients, and should be considered an 
alternative way of providing adequate nutrition support to suitable 
patients. 
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